The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) spanning five years because of Washington's demand for sensitive data.
The decision came to light following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesman has since clarified that the US was demanding access to biological samples for research and commercial gain while was not willing to share the benefits from future treatments.
"We will now turn to the challenging and unfortunate process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has called for further dialogue to secure a deal acceptable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision follows a comparable situation in Kenya, where a court suspended a related deal with the US after legal challenges were filed about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its spending was "wasteful" and his government was pursuing direct bilateral agreements to boost openness and responsibility.
According to statements, Sixteen nations in Africa have so far signed similar health pacts, constituting more than $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to provide its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery with no assurance that the final treatments would be accessible to our people should a future pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were undermining structures previously set up via the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to deal with future pandemics.
"This system is intended to guarantee that when a country provides its information, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to create them."
The government's concerns regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We welcome ongoing dialogue with our American counterparts on how future co-operation might be arranged in a way that respects the independence and dignity of both nations."
Health Experts Response
A leading public health body stated it understood the official position, but recommended that talks must proceed since much of the country's HIV programmes relied on foreign aid.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," the group commented.
The situation emphasises the complex tensions between receiving crucial international aid and protecting local interests in an ever more data-driven world.